Le Lézard
Classified in: Health
Subject: FDA

Tirosint®-SOL Now Available to Treat Hypothyroidism in the U.S.

PARSIPPANY, N.J., Feb. 27, 2019 /PRNewswire/ -- IBSA Pharma Inc. announced that its Tirosint-SOL (levothyroxine sodium) oral solution is now available in the US market for the treatment of hypothyroidism and pituitary thyrotropin suppression.

Tirosint-SOL is the first and only liquid levothyroxine formulation approved by the FDA and is indicated for patients of all ages.  Levothyroxine is a hormone that is normally produced by the thyroid gland. It is used to treat patients who suffer from hypothyroidism or inadequate levels of thyroid stimulating hormone (TSH).

Tirosint-SOL is the latest product to be launched in the US by the IBSA Pharma Inc., a fully-owned subsidiary of IBSA Institute Biochemique SA. Tirosint-SOL's unique liquid formulation is made without excipients such as dyes, wheat starch (gluten), lactose, alcohol, sugar and others that may contribute to tolerability and absorption issues. It is packaged in monodose ampules in 12 different dosage strengths, including a 13 mcg/mL dose. Tirosint-SOL may be administered either directly into the mouth or diluted in a glass of water.

"Tirosint-SOL  is the only FDA approved oral liquid levothyroxine therapy. It will be available through participating mail order  and retail pharmacies starting March 1st, " stated Aldo Donati, CEO of IBSA Pharma. Tirosint-SOL has been studied extensively in Europe and the value of its unique formulation demonstrated by several clinical studies that have been published in scientific journals.  

"Tirosint-SOL represents an evolution in hypothyroidism treatment. While levothyroxine therapy has been available for decades, this is the first FDA-approved liquid levothyroxine formulation," said Dr. Murray Ducharme, Professeur Associé, Faculté de Pharmacie at the University of Montreal.  "This easy-to-swallow option will provide a useful new option for many patients who may benefit from a liquid rather than an oral solid version of this proven therapy."

IBSA offers several programs to provide patients who need Tirosint-SOL, with cost-effective access to Tirosint-SOL. For eligible patients with commercial insurance, the Tirosint-SOL Copay Savings Card may reduce the cost of Tirosint-SOL to as little as $15 per month of therapy. For patients without insurance or with high copays or deductibles, the Tirosint Direct Program is available through participating mail order pharmacies and offers the lowest cash price available. Additional information can be found at www.tirosintsol.com. IBSA also offers a Patient assistance Program (PAP) for qualifying indigent patients. Additional information can be found at http://www.ibsapap.com/.

IBSA Pharma is part of IBSA Group, which is headquartered in Lugano, Switzerland. The company is a world leader in the treatment of thyroid disease and has a diversified product portfolio of prescription drugs. With products on five continents and in over 80 countries, IBSA manufactures 14 million vials of hormones, 300 million soft gel capsules and 60 million packages of finished products every year. IBSA has a commitment to scientific research and improving the health of patients.

Important Safety Information



Warnings and Precautions   

Limitations of Use

Adverse Reactions 
Adverse reactions associated with TIROSINT-SOL are primarily those of hyperthyroidism due to therapeutic overdosage including: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash.

For more information, visit www.ibsagroup.com/media.

*For Full Prescribing Information, visit www.TirosintSOL.com


IBSA Institut Biochimique SA, Lugano, Switzerland (PRNewsfoto/IBSA Pharma, Inc.)


These press releases may also interest you

at 04:50
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Over-the-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand...

at 04:45
Financial Recovery Group, Inc. (FRG), an industry leader in providing health plans and physicians groups with interactive software to improve financial performance, has achieved HITRUST® CSF Certified status. The designation means FRG's information...

at 04:15
Outdoor accessories supplier Never Limited Products, LLC has begun promoting a simple two-step system for sanitizing reusable work or outdoor gloves, using its popular portable Glove Dryer plus inexpensive hydrogen peroxide. The result is gloves...

at 04:05
In 2016, Polpharma Biologics acquired Dutch based Bioceros and their proprietary cell line development platform CHOBC®, as well as their comprehensive discovery, process development and analytical capabilities. Polpharma Biologics is now taking a...

at 04:05
The global biodefense market is expected to grow by USD 3.22 billion as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. Steady growth is...

at 04:05
The global COVID-19 drug delivery devices market size is expected to reach USD 2.15 billion by 2027, according to a new report by Grand View Research, Inc., expanding at a CAGR of 8.1% from 2022 to 2027. The market is expected to gain significant...

News published on 27 february 2019 at 08:03 and distributed by: